(Fighting New Coronary Pneumonia) German and U.S. pharmaceutical companies announced that their joint-developed mRNA vaccine phase III trial has an effective rate of 90%

  China News Agency, Berlin, November 9th (Reporter Peng Dawei) BioNTech and Pfizer announced on the 9th that the preliminary results of the Phase III clinical trial of the new crown mRNA vaccine jointly developed by them show that the vaccine is effective in preventing health problems. The test subjects are infected with the new coronavirus at an effective rate of more than 90%.

  Headquartered in New York, Pfizer is a world-renowned pharmaceutical company.

BioNTech (BioNTech) is a next-generation immunotherapy company located in Mainz, Germany, dedicated to pioneering the development of new therapeutic drugs for cancer and other serious diseases.

In March 2020, Pfizer and Biotech Technologies began to collaborate on the development of a new coronavirus vaccine based on mRNA.

  The two companies stated in a statement that day that the candidate vaccine code-named BNT162b2 obtained the results of the above-mentioned Phase III trial. The Phase III trial began on July 27, and a total of 43,538 subjects have participated in the trial so far.

As of November 8, 38,955 of the above subjects had received the second dose of vaccine.

Among them, about 42% of the subjects globally have racial and ethnic diversity, and the proportion of American subjects is 30%.

The statement stated that the subjects showed no serious safety issues, and data on safety and side effects are still being collected.

  The preliminary results analysis report of the third phase of the trial announced that day was completed by an independent external data monitoring committee (Data Monitoring Committee).

  The two companies stated in the statement that they will apply to the U.S. Food and Drug Administration (FDA) for an emergency use authorization (EUA) after the necessary safety requirements are met.

This action is expected to be completed within the third week of November.

  Regarding the progress made by German and American pharmaceutical companies in the development of mRNA vaccines, Marilyn Addo, head of infectious diseases at the Hamburg-Eppendorf University Medical Center in Germany, said that because the two companies have not yet released relevant preliminary data, people are currently Little is known about the details of this vaccine. For example, data on subjects of different ages have not been released.

She said that accurate data is needed before the final evaluation of this vaccine can be made.

(Finish)